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Cell-selective targeting is expected to enhance effectiveness and minimize side effects of 
cytotoxic agents. Functionalization of drugs or drug nanoconjugates with specific cell ligands 
allows receptor-mediated selective cell delivery. However, it is unclear whether the 
incorporation of an efficient ligand into a drug vehicle is sufficient to ensure proper 
biodistribution upon systemic administration, and also at which extent biophysical properties 
of the vehicle might contribute to the accumulation in target tissues during active targeting. To 
approach this issue, we have compromised the structural robustness of self-assembling, protein 
only nanoparticles targeted to the tumoral marker CXCR4, by reducing the number of histidine 
residues (from 6 to 5) in a histidine-based architectonic tag. By such engineering, the structure 
of the resulting nanoparticles, but not of building blocks, results destabilizedweakened. Upon 
intravenous injection in animal models of human CXCR4+ colorectal cancer, the administered 
material losses the ability to accumulate in tumor tissue, where is only transiently found, while 
it instead deposited in kidney and liver. Therefore, precise and efficient cell-targeted delivery 
requires not only the incorporation of a proper ligand that promotes receptor-mediated 
internalization, but also, unexpectedly, its maintenance of a stable multimeric nanostructure 
that ensures high ligand exposure and long residence time in tumor tissue   
  
  




Targeting of drugs for precision medicine is a widespread popular challenge, since proper drug 
biodistribution is expected to enhance effectiveness and minimize undesired side effects. [1] 
This is especially desirable regarding cytotoxic drugs, as those used in cancer, whose 
administration is associated to severe toxicities. It is assumed that functionalizing drugs or drug 
complexes with selective cell ligands would confer active targeting and ensure their 
accumulation in target cells and organs where such receptor is overexpressed. However, the 
biodistribution analyses of antibody drug conjugates and other similarly targeted drug 
constructs have repeatedly revealed that the fraction of administered agent reaching the target 
organ is limited to around 1 %. [2] On the other hand, physical properties of drug vehicles such 
as surface charge, geometry and size, among others, appear as key factors influencing the tissue 
accumulation pattern upon systemic administration when the delivery platform is based on 
passive targeting,, [3, 4] when the delivery platform is based on passive targeting, for instance by 
exploiting the enhanced permeability and retention (EPR) effect. [5] However, the weight of 
material nanoscale properties of the material itself in determining biodistribution in presence of 
selective cell-ligands, that is, during active targeting, remains unsolved, despite its critical value 
in the design of new drug delivery systems. Combining efficient homing peptides with carrier 
materials in their optimal configuration might largely enhance the local accumulation in target 
tissues above the ~1 % threshold and thus increase precision and effectiveness in the delivery 
process.  
To discriminate between the roles of the ligand and the architecture of the vehicle itself in the 
process of active tumor targeting, we have engineered the modular protein T22-GFP-H6 into 
related constructs and tracked selected resulting variants upon administration in animal models 
of human colorectal cancer. Such fusion protein is composed by T22, a potent ligand of the cell 
surface cytokine receptor CXCR4, [6] overexpressed in several metastatic human cancers, [7] a 
fully fluorescent GFP and a C-terminal polyhistidine tail. T22-GFP-H6 spontaneously self-
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assembles in physiological conditions as 12 nm-nanoparticles, formed by around 10 copies of 
the polypeptide, organized in a toroid architecture. [8, 9] and with some extent of structural 
flexibility. [9] When administered intravenously in orthotropic mice models of human CXCR4+ 
colorectal cancer the fluorescent nanoparticles accumulate in primary tumor and metastatic foci 
at unusually high levels, estimated to represent more than 85 % of the whole-body detected 
fluorescence. [6] Used as a carrier of the cytotoxic drug floxuridine (FdU), the nanoconjugate 
T22-GFP-H6-FdU reduces the volume of primary tumor, prevents the development of 
metastasis and precisely destroys already formed metastatic foci in absence of detectable 
systemic toxicity. [10] Similar anti-tumoral effectiveness has been observed when the 
nanoparticles deliver, accommodated in the building blocks by genetic fusion, pro-apoptotic 
factors and other antitumoral peptides. [11] 
Interestingly, the self-assembling of T22-GFP-H6 and related materials is driven by the 
overhanging polyhistidine tails that coordinate divalent cations from the media to promote 
stable cross-molecular protein interactions. [12] If the structure of the nanoparticle beyond the 
ligand itself, is relevant for precise targeting, destabilizing the supramolecular complex by 
modifying the histidine tail sequence would result in a potentially altered biodistribution map 
of the material, even if this material still contains the active CXCR4 ligand T22. The 
comparison of the fluorescence maps of T22-GFP-H6 and one of its less stable variants T22-
GFP-H5T, once intravenously (iv) injected in colorectal cancer models, revealed that the 
presence of the targeting peptide T22 in the protein, although necessary for CXCR4-mediated 
cell binding, [6] is not sufficient for a proper tumor targeting. On the contrary, the 
nanoarchitecture of the material as an oligomeric supramolecular complex has a critical and 
unexpected impact on the fate, dynamics and final accumulation of the material at the different 
organs, allowing the desired biodistribution upon administration. Therefore, nanoscale 
organization is an unexpected key determinant of not only passive but also active targeting. 
  




Being the H6 tail critical for nanoparticle formation, [13] this end-terminal peptide was replaced 
in T22-GFP-H6 by alternative histidine-rich peptides of similar length, with lower content of 
histidine (His) residues (Table 1). Since Hhis residues promote the cross-molecular protein-
protein interactions that sustain the architecture of the oligomers, [12] the reduction in the 
number of Hhis residues was expected to generate less stable nanoparticles. Then, T22-GFP-
H3A, T22-GFP-H5T and T22-GFP-H5E fusions were designed, constructed and expressed in 
bacteria as soluble protein versions, for comparison with the parental T22-GFP-H6. The 
alternative His-rich segments were selected according to previous reports indicating that His 
residues, intersected with hydrophobic or negatively charged residues, could be still retained in 
Ni+2-based chromatography purification that uses His residues as binders. [14] 
All proteins (the parental and the derived versions) were produced as proteolytically stable full-
length forms of expected molecular masses (Figure 1A, Table 1), and the specific fluorescence 
emission values were of the same order of magnitude than that shown by T22-GFP-H6 (Table 
1). This fact indicated that native-like conformation was reached in individual GFP-based 
building blocks. The purification by His-tag-based affinity chromatography was efficient in all 
cases, but the concentration of imidazole required to elute the proteins was different in each 
case (Table 1). It was, being lower, as expected, at lower His residue content. The H5T-tagged 
polypeptide was eluted at an imidazole concentration that represented 86 % of that required by 
H6-tagged materials, indicating that the strength of His-divalent cation interactions was 
weakened down to this relative level compared to the H6 tag. T22-GFP-H3A and T22-GFP-
H5E required even less imidazole concentration for detachment from immobilized Ni, 
representing 68 % and 61 % of that required for T22-GFP-H6, respectively (Table 1). This fact, 
and the resulting quantitative data about imidazole-mediated detachment, confirmed that the 
strength of His-based cross-molecular interactions can be regulated by the number of His 
residues in overhanging tags. 
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In this context, sSince the self-assembling of His-tagged T22-carrying nanoparticles is based 
on the ability of His residues to interact with each other’s through divalent cations from the 
media, the quantitative reduction in the interactivity with Ni+2 of the engineered proteins should 
be translated into nanoparticles less stable than T22-GFP-H6, if they were actually formed. 
When checking the self-assembling of the materials in the standard carbonate buffer, all 
proteins spontaneously formed nanoparticles (Figure 1B, Figure 1C, Table 1), with 
hydrodynamic sizes and Z-potential values similar to those shown by the parental T22-GFP-
H6 (Table 1). The microscopy scrutiny of all nanoparticles revealed a toroidal architecture 
(Figure 1C), compatible with the previously obtained molecular model of T22-GFP-H6. [8] 
However, when challenging the assembled materials with ionic strength, T22-GFP-H3A and 
T22-GFP-H5E, those with less molecular interactivity with ions (Table 1), immediately 
disassembled into smaller materials with sizes compatibles with the dimeric form of GFP 
(around 7 nm, Figure 1B). This was , indicative of weak cross-molecular interactions between 
building blocks. Instead, T22-GFP-H5T tolerated well the presence of salt in the media. 
However, this construct showed high instability during freezing and thawing and it partially 
disassembled as structures smaller than 12 nm (Figure 2 A), of size comparable to assembling 
intermediates described for T22-GFP-H6. [9] Some of these structures were also observed under 
TEM (Figure 1C). These small forms appeared together with a minor occurrence of larger 
protein clusters, indicative of supramolecular instability (Figure 2A), and conformational 
impact linked to freezing and thawing-induced damage. [15] To further assess the differential 
stability between H6- and H5T-based nanoparticles,  they were incubated for 24 h at 37 ºC in 
human sera, to better reproduce the conditions of in vivo administration. As observed (Figure 
2A), T22-GFP-H5T (but not T22-GFP-H6) nanoparticles dissociated under these conditions, 
confirming again the lower stability of the H5T material. Such weaker structural robustness was 
not due to defects in the folding of H5T building blocks, as thermal stability analysis indicated 
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that both modular polypeptides were equally stable (or even T22-GFP-H5T lightly more stable 
than T22-GFP-H6, Figure 2B). This was in agreement with the fluorescence data from Table 1. 
In the light of these observations, we decided to comparatively determine the influence of 
nanoparticle stability on in vivo biodistribution of bothby comparing T22-GFP-H6 and the less 
stable T22-GFP-H5T materials. nanoparticles. Importantly, the modular polypeptides 
themselves, acting as building blocks of the materials, were both proteolytically robust resistant 
(Figure 1), structurally stable (Figure 2 C), targeted to the same tumoral marker CXCR4 through 
T22 [6, 8, 16], and only differ in a few structural amino acids at their C-termini. Additionally, the 
thermal stability analysis indicated that both modular polypeptides were equally stable (or even 
T22-GFP-H5T lightly more stable than T22-GFP-H6, Figure 2B), in agreement with the 
fluorescence data from Table 1. Also, when both proteins were incubated in human serum their 
electrophoretic motility of these proteins did not change in serum, as well as their specific 
fluorescence (Figure 2C). Moderate increases in the emission values might be indicative of 
structural readjustments of the building blocks, without disturbing protein integrity and folding. 
All these data confirmed that the sequence that despite the differences between in both proteins 
affected the stability of the nanoparticles but not that of the monomersbuilding blocks were 
both structurally robust and competent, making them suitable for comparative analysis in vivo. 
In addition, the interactivity between T22 and CXCR4 (Figure 2D) and the ability of the peptide 
to mediate receptor specific endosomal internalization of nanoparticles (Figure 2E) was were 
not disturbed by the modifications in the His-rich tailfully confirmed in both constructs. 
When both T22-GFP-H6 and T22-GFP-H5T were administered iv in mice bearing 
subcutaneous SP5 CXCR4+ colorectal tumors, the accumulation pattern of both proteins in 
tumor was clearly divergent. While T22-GFP-H6 was progressively found in tumor (Figure 
3A), with a plateau of fluorescence reached at 24 h, T22-GFP-H5T was only transiently found 
in tumoral tissues at 5 h post administration, followed by a fast decline (Figure 3B). This might 
be indicative of lake or poor cell uptake in the tissue, through which the material appears to 
Con formato: Fuente: Cursiva
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transiently pass by. Moreover, a background (off-target) fluorescence emission of T22-GFP-
H5T was observed in liver and kidney, having an increase during the 24-48 h period post-
injection, whereas T22-GFP-H6 emission during this period was declining in theseis organs. 
The much more extensive and sustained T22-GFP-H6 tumor accumulation was clearly 
evidenced by the quantitative ex vivo analyses of relevant organs (Figure 3B). Thus, T22-GFP-
H6 reached a tumor exposure (AUC = 5.04x108 emitted fluorescence intensity –FLI- units / 
hour) 2.7 fold higher than T22-GFP-H5T (AUC = 1.90x108) (Figure 4, Table 2). The much 
more extensive and sustained T22-GFP-H6 tumor accumulation was clearly evidenced by the 
quantitative ex vivo analyses of relevant organs (Figure 3B). Thus, T22-GFP-H6 reached a 
tumor exposure (AUC = 5.04*108 FLI units x hour) 2.7 fold higher than T22-GFP-H5T (AUC 
= 1.90*108) (Figure 4 and Suppl. Table 1). Mostly, background signal was observed in other 
non-target organs, except for T22-GFP-5HT in the 24-48 h period, which registered increases 
of 64% in the kidney and 14% in the liver (Figure 3C and 4B and Table 2). Consequently, T22-
GFP-H6 had an AUC ratio  tumorratio tumor/(kidney+liver) of 2.2, while in T22-GFP-H5T this 
ratio was 0.8 (Figure 4C).  Since the divergence in the biodistribution maps of the two tested 
related proteins is irrespective of the common N-terminal ligand (T22, binding CXCR4) but 
dependent on the amino acid sequence of the C-terminal architectonic peptide, we can conclude 
that a multimeric organization of the modular proteins offers an appropriate nanoscale 
presentation of the ligand, with a geometry supporting its targeting function in the body.   
 
  
Con formato: Superíndice 
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Two N-terminal homologous GFP modular proteins, namely T22-GFP-H6 and T22-GFP-H5T 
(Table 1), targeted to CXCR4 tumors, showed a very dissimilar biodistribution upon iv 
administration in mice models of human, CXCR4+ colorectal cancer (Figure 3). Both protein 
versions are proteolytically stable upon bacterial production (Figure 1) and upon incubation in 
human serum (Figure 2 C), showing no loss, in any case, of relevant protein fragments that 
might abort the cell binding process. Both polypeptides are also highly fluorescent (Table 1), 
show robust structural stability (Figure 2 B) and spontaneously assemble as regular 
nanoparticles of comparable size and physicochemical properties (Figure 1C, Table 1) that 
equally penetrate CXCR4+ cells in culture (Figure 2 D). However, the minor sequence 
differences at the His-rich C-terminal peptide (Table 1), responsible for cross-molecular 
interactions and divalent cation-mediated nanoparticle formation [12] resulted weakened in T22-
GFP-H5T relative to the parental T22-GFP-H6, to around 86 % (Table 1). This is because of 
the reduction in the number of His residues in such architectonic peptide, from 6 to 5, which 
minimizes the binding of the protein to divalent cations, including the Ni+2 of the purification 
columns (Table 1). Other two constructs with 5 and 3 His residues in the C-terminus, 
respectively, are not able to form nanoparticles in high salt buffer (Figure 1B), indicative of the 
inability of these agents to form stable interactions. Although in contrast, T22-GFP-H5T was 
stable in salt, the long-term storage of this material at -80ºC and 24 h incubation in human 
serum, at 37ºC  in the assembled form, indicated a structural instability of T22-GFP-H5T 
nanoparticles (Figure 2 A) that was not apparent by the mere hydrodynamic size analysis upon 
biological fabrication (Figure 1B).  
Such less stable T22-GFP-H5T nanoparticles reached the target tumor tissue at 5 h post iv 
administration (Figure 3). However, they failed to accumulate in the tumor (being undetectable 
at 24 h), while displaying a much lower tumor exposure than the parental H6-tagged protein 
(Figure 4). Moreover, the amounts of this protein were progressively fading in tumor tissue, 
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while an increased in its fluorescence signal was foundobserved, at later times and at important 
levels, in non-tumor organs such as liver and kidney. Therefore, T22-GFP-H5T had a lower 
accumulation in tumor than in non-tumor tissues (AUC ratio = 0.8). This was in sharp contrast 
with T22-GFP-H6, for which most of the injected dose accumulated in tumor rather than in 
non-tumor tissues (AUC ratio = 2.2) (Figure 4, Table 2). Thus, despite T22-GFP-H6 started 
their tumor uptake at later times, it reached a total tumor exposure 2.7 fold higher than this 
achieved for T22-GFP-H5T, and also maintained a high fluorescence exposure in tumor tissue 
beyond 48 h. In addition to this, the injected equal dose and highly similar fluorescence 
emission of the two compared proteins lead to much higher tumor exposure for T22-GFP-H6 
than in non-tumor tissues, while the opposite happened for T22-GFP-H5T, suggesting a more 
intense and faster clearance from the body of T22-GFP-H5T, since its total (tumor + non-tumor) 
fluorescence emission showed a 43 % reduction as compared to total T22-GFP-H6 FLI 
emission (Figure 4). In this regard, the higher accumulation in kidney and liver at longer times 
(48 h) for T22-GFP-H5T, together with its lower nanostructure stability as determined in vitro 
(Figure 2A), strongly suggests the possible occurrence of a much higher renal excretion and/or 
hepatic metabolism than T22-GFP-H6. The tumor accumulation pattern followed by T22-GFP-
H6 was in agreement with previous experiments in related mice models. [8] This was indicative 
of the robustness of the material regarding biodistribution to tumor tissue, leading to high 
exposure in that tissue by achieving a high uptake peak and a long residence time, while 
displaying low uptake in non-tumoroff-target tissues.  [6, 8, 17, 18] In fact, the present data also 
suggested a lack of intracellular penetration of T22-GFP-H5T in tumor. When stable 
nanoparticles that effectively internalize in target CXCR4+ tumors cells are administered, [6] a 
residence time of around 48 hours in tumor is consitently observed. During this time period, the 
nanocarrier is problably degraded within uptaking cells. [19] A 48 h residence time or longer, 
occurs also in therapeutic protein-only nanoparticles targeting CXCR4+ cancer cells. [20]  The 
shorter tumor residence time of T22-GFP-H5T suggests that this protein carrier, despite 
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interacting with the CXCR4 receptor through its T22 ligand, is not effectively internalized in 
target cells. Consistently, an early and short residence time of GFP-H6 (lacking the T22 ligand) 
in tumor has been also observed. [21]  
 
These data were compatible with a robust structure of T22-GFP-H6 nanoparticles compared to 
a progressively disassembling T22-GFP-H5T materials, provided the nanostructure is assumed 
as a critical component of the active targeting process. While the role of nanostructure as an 
element influencing passive targeting has been largely discussed and recognized, [4, 22] its 
potential impact on active targeting (that mediated by a cell-surface ligand) has been a rather 
neglected issue. Nanoscale organization of a targeted material might enhance its interaction 
with target cells by the multimeric binding of nanoparticles to cell surface receptor molecules 
on the cell surface. [23, 24] Multivalent ligands generally show lower dissociation rates than 
individual versions ligands in the interaction with the receptor, [25] apart from a cooperative cell 
binding that promotes a more efficient early interaction and endosomal internalization. [26] Such 
cooperativity in both signalling and internalization of artificial constructs has been already 
described in different therapeutic platforms, [24, 27] what could be specially efficient in the case 
of symmetrically ordered materials. [28] In the case of recombinant proteins, multivalent 
presentation of ligands in supramolecular constructs might be more efficient than monovalent 
versions, [29] what has been already discused in the context of virus-like presentations of cell 
interactors and the consequent enhanced endosomal cell uptake. [26] In this regard, the results 
presented here support again the convenience of multivalent presentation, that also enhances 
the specificity in cell-receptor recognition. In this context, hybrid nanoparticles in which 
peptides R9 (an unspecific cell-penetrating peptide) and T22 (a specific CXCR4 ligand) are 
combined show lower CXCR4-specificity than T22 only-based nanoparticles. [13] Besides, the 
size increase derived from oligomerization, in the case of the modular proteins described here 
from ~4 nm (the hydrodynamic size of a GFP monomer) to ~12 nm, above the renal cut-off or 
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~6-8 nm, [18] might also increase circulation time and in consequence opportunities for a tight 




The occurrence of an effective ligand of a tumor cell marker is necessary but not sufficient to 
ensure a proper tumor biodistribution of functional proteins upon systemic administration, as 
proved here by using a model self-assembling protein. Contrarily, a supramolecular architecture 
of such targeted polypeptide, in form of multimeric nanoscale materials, enables the tumor 
homing peptide, here modelled by the CXCR4 ligand T22, to drive the accumulation of the 
material in the target tumor tissue. Several factors, including the multimeric regular presentation 
of the ligand and the nanoscale size of the complex are probably involved in the complex 
process of active targeting. In active targeting, the administered material needs to overcome 
several biological barriers, including renal and hepatic clearance, to achieve higher exposure 
and residence time in tumor. The concept presented here might represent a convincing 
explanation of the poor biodistribution so far reached by tumor-targeted medicines, including 
antibody-drug conjugates. In addition to this, it is offering a potential developmental roadmap 
for the improvement of these drugs, of high intrinsic therapeutic potential, to reach satisfactory 
efficiencies in the clinical context.  
 
 
((References should be superscripted and appear after punctuation.[1,2] If you have used 
reference management software such as EndNote to prepare your manuscript, please convert 
the fields to plain text by selecting all text with [ctrl]+[A], then [ctrl]+[shift]+[F9]).[3–5] Please 
define all acronyms except IR, UV, NMR, and DNA or similar (for a complete list of 
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“Author Guidelines” section.)) 
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Experimental Section  
Genetic design, protein production and purification 
The genetic design of newly hHis-derived modular proteins was based on the parental T22-
GFP-H6 construction. The C-terminal H6 poly-Hhis tail was exchanged for alternative his-rich 
human peptides under specific criteria (explained during the work). The already displayed 
abbreviations -H6, -H3A, -H5T and -H5E correspond to HHHHHH, HAAHAH, 
HTHTHTHTH and HEHEHEHEH amino acid sequences respectively. Nomenclature has been 
established from N to C terminal according to their modular organization. All protein sequences 
were designed in house as codon-optimized genes, synthetized and inserted into pET22b 
plasmids using NdeI and HindIII restriction enzymes and provided by Geneart (ThermoFisher).  
All fusion proteins were transformed by heat shock for 45 second at 42 ºC in E. coli Origami B 
(BL21, OmpT-, Lon-, TrxB, Gor-; Novagen). Transformed cells were then grown at 37 ºC 
overnight in LB (Lysogeny Broth) and encoding proteins produced at 20 ºC overnight upon 
induction with 0.1 mM of Isopropyl-b-D-Thiogalactopyronaside (IPTG) when the OD550 
reached 0.5-0.7. Cells were then harvested by centrifugation for 15 min (5,000g at 4 ºC) and 
stored at -80ºC until use.  Pellets were then thawed and resuspended in Wash buffer (20 mM 
Tris, 500 mM NaCl, pH = 8) in presence of protease inhibitors (Complete EDTA-free; Roche 
Diagnostics). Cell disruption was subsequently performed by sonication (0.5-on, 0.5-off for 5 
min) at 10 % of amplitude (Branson Digital Sonifier®), and the soluble fraction was separated 
by centrifugation for 45 min (15.000g at 4ºC) and filtered using a pore diameter of 0.45 and 
0.22 m consecutively. Proteins were finally purified by Immobilized Metal Affinity 
Chromatography (IMAC) in an ÄKTA pure system (GE Healthcare) using HiTrap Chelating 
HP 5 ml columns (GE Healthcare). Protein elution was achieved by a linear gradient of Elution 
buffer (20 mM Tris, 500 mM NaCl, 500 mM Imidazole, pH = 8) and rinsed protein dialyzed 
against sodium carbonate (166 mM NaCO3H, pH = 8) and sodium carbonate with salt (166 mM 
NaCO3H, 333 mM NaCl, pH = 8) buffers.  




Protein purity, integrity and concentration 
Protein purity was determined by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) and Western Blot (WB) immunoassay with an anti-GFP monoclonal antibody 
(Santa Cruz Biotechnology). Protein integrity was also analyzed by Matrix-Assisted Laser 
Desorption Ionization Time-of-Flight (MALDI-TOF) mass spectrometry and concentration 
determined by Bradford’s assay.  
 
Volume size distribution, Z-Potential and fluorescence emission. 
Volume size distribution (VSD) and protein surface charge (Zp) of all proteins were determined 
by Dynamic Light Scattering (DLS) and Z-potential measurements respectively at 633 nm and 
25ºC in a Zetasizer Nano ZS (Malvern Instruments Limited) using ZEN2112 3 mm quartz batch 
cuvettes and DTS10170 capillary cells respectively. Measurements were performed in triplicate 
for error estimation and VSD peak values referred to the average mode of the populations with 
a rendered standard error lower than 0.01. Fluorescence emission of each GFP variant was 
determined at 513 nm using an excitation wavelength of 488 nm with a Varian Cary Eclipse 
Fluorescence Spectrophotometer (Agilent Technologies). For that, all the proteins were equally 
diluted in the corresponding sodium carbonate buffer w/o salt until 1 mg/ml in a final volume 
of 100 µl.  
 
Ultrastructural morphometry 
The nanoscale morphometry (size and shape) of self-assembled nanoparticles was determined 
at nearly native state, both by deposition on silicon wafers with field emission scanning electron 
microscopy (FESEM) and by negative staining with transmission electron microscopy (TEM). 
Drops of 3 µl of T22-GFP-H6, T22-GFP-H3A, T22-GFP-H5T and T22-GFP-H5E samples 
diluted at 0.4 mg/mL in sodium carbonate buffer were directly deposited on silicon wafers (Ted 
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Pella Inc., Reading) for 30 seconds, excess of liquid was blotted with Whatman filter paper 
number 1 (GE Healthcare), air dried for few min, and immediately observed without coating 
with a FESEM Zeiss Merlin (Zeiss) operating at 0.8 kV and equipped with a high resolution in-
lens secondary electron detector. Drops of 3 µl of the same four samples were directly deposited 
on 200 mesh carbon-coated copper grids (Electron Microscopy Sciences, Hatfield) for 30 sec, 
excess blotted with Whatman filter paper, contrasted with 3 µl of 1 % uranyl acetate 
(Polysciences Inc.) for 1 min, blotted again and observed in a TEM Jeol 1400 (Jeol Ltd.) 
operating at 80 kV and equipped with a Gatan Orius SC200 CCD camera (Gatan Inc.). For each 
sample and technique, representative images of a general field and a nanoparticle detail were 
captured at high magnifications (from 100,000x to 600,000x). 
 
Determination of GFP chromophore fluorescence 
The GFP chromophore fluorescence dependence on the temperature of each protein was also 
evaluated. Fluorescence spectra were recorded in a Varian Cary Eclipse spectrofluorimeter 
(Agilent Technologies). A quartz cell with 10 mm path length and a thermostated holder was 
used. The excitation slit wass set at 2.5 nm and emission slits were set at 5 nm. ex was set at 
488 nm. Protein concentration was 0.2 mg/ml in the corresponding buffer. 
 
Structural stability of protein constructs upon human serum incubation 
T22-GFP-H6 and T22-GFP-H5T protein nanoparticles were incubated at 37ºC with agitation 
(250 rpm) at proportion 1:1 in relation to human serum (Sigma-Aldrich) for 24 and 48 h. Protein 
VSD was determined at 24 h by a Zetasizer Nano ZS (Malvern Instruments Limited) and protein 
fluorescence and motility by a Varian Cary Eclipse spectrofluorometer (Agilent Technologies) 
and WB immunoassay respectively. T22-GFP-H6 and T22-GFP-H5T proteins were incubated 
at 37ºC with agitation (250 rpm) at proportion 1:1 in relation to human serum (Sigma-Aldrich) 
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for 48 h. Protein fluorescence emission and motility were determined by using a Fluorescence 
Spectrophotometer and WB blot immunoassay respectively as previously described.  
 
Protein internalization  
HeLa CXCR4+ cells (ATCC® CCL-2TM) were cultured in 24-well plates (60.000 cells/well 
during 24 h for different time/concentration assays, in MEM Alpha 1x GlutaMAXTM medium 
(Gibco) supplemented with fetal bovine serum (FBS) at 37ºC in a 5 % CO2 humidified 
atmosphere, until reaching a confluence of 70 %. Protein internalization was monitored at 
different concentrations (50 and 1000 nM) and times (1 and 24 h). After protein exposure, cells 
were detached and external hooked protein removed by adding Trypsin-EDTA (Gibco®) at 1 
mg/mL for 15 min and 37ºC. Intracellular protein fluorescence was determined by flow 
cytometry using a Fluorescence Assisted Cell Sorting (FACS)-Canto system (Becton 
Dickinson) at 15 mW with an air-cooled argon ion laser exciting at 488 nm. Measurements 
were performed in duplicate. Additionally, the specific protein CXCR4-mediated 
internalization was proved by the addition of the receptor antagonist AMD3100 [30] that inhibits 
the interaction between T22 and CXCR4. This chemical compound was added at a final 
concentration of 500 nM (10 times protein concentration) for 1 h prior to protein incubation at 
50 nM. 
 
In vivo biodistribution assays 
All in vivo experiments were approved by the institutional animal Ethics Committee of Hospital 
Sant Pau. Five-week-old female Swiss nu/nu mice weighing between 18 and 20 g (Charles 
River, L-Abreslle) and maintained in specific-pathogen-free (SPF) conditions, were used for 
the in vivo biodistribution studies. We used a subcutaneous colorectal cancer mouse model 
derived from the patient sample SP5. To generate this model, we implanted in the mouse 
subcutis 10 mg of SP5 tumor tissue obtained from donor animals. When tumors reached a 
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volume of approximately 500 mm3 we performed biodistribution assays of T22-GFP-H6 and 
T22-GFP-H5T nanoparticles at three different times after nanoparticle injection, namely 5, 24 
and 48 h. Mice received 100 µg single iv bolus of T22-GFP-H6 (n=2) or 100 µg single iv bolus 
of T22-GFP-H5T (n=2) in sodoum carbonate buffer with salt. Control animals (n=2) were iv 
administered with 150 µl of the same buffer.  
At 5, 24 and 48 hours after the iv injection, mice were euthanized and subcutaneous tumors and 
normal organs, including lung and heart, kidney, liver, and bone marrow were collected. 
Biodistribution of GFP fluorescent nanoparticles was determined measuring ex vivo the 
fluorescence emitted by tumors and normal organs using the IVIS Spectrum equipment 
(PerkinElmer Inc, Waltham). The fluorescent signal (FLI) was first digitalized, displayed as a 
pseudocolor overlay, and expressed as radiant efficiency. FLI values were calculated 
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Figure 1. Physicochemical characterization of his-rich protein constructs. A. Mass 
spectrometry of purified samples indicating protein molecular weight of both monomeric and 
dimeric forms. Protein integrity was also assessed by Coomassie blue staining (Co) and anti-
GFP WB respectively. Numbers indicate molecular masses (in kDa) of markers. The inset 
illustrates the modular architecture of the polypeptides, Hn indicating tails with variable number 
of His residues. B. Size distribution of his-rich protein constructions dialyzed against standard 
sodium carbonate buffer with or without salt. Modal peak size (nm) and PDI (Polydispersion 
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Index) mean± standard error values are indicated. C. FESEM and TEM imaging of his-rich 
protein materials in sodium carbonate buffer. Representative images showing morphometry and 
architecture of the nanoparticles are displayed at two different magnifications for each 
technique. Scale bars represent 20 nm.    
 
Figure 2. Structural and functional stability of protein nanoparticles. A. Size distribution of 
T22-GFP-H6 and T22-GFP-H5T nanoparticles upon purification and after storage a -80ºC, or 
upon incubation in human sera. Arrows indicate . Modaldisassembling. Modal peak size (nm) 
and PDI (mean ± standard error) values are indicated. B. Decrease of chromophore fluorescence 
intensity (at 513 nm) of T22-GFP-H6 and T22-GFP-H5T versus temperature, measured at λex 
= 488 nm. The slope decays from 50 to 80ºC was registered in the plot. C.  Protein stability 
upon 48 h incubation in human serum at 37ºC. Fluorimetry (up) and western blot 
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immunodetection (bottom) were used to determine protein integrity. Numbers indicated on top 
of plot bars represent variations of fluorescence intensity in percentage relative to original 
samples. D. Internalization of different amounts of protein nanoparticles in cultured HeLa cells, 
determined at 1 and 24 h post exposure. E. Inhibition of CXCR4+ cell binding mediated by the 
CXCR4 antagonist AMD3100. 
 
Figure 3. Tumor and non-tumoral organ biodistribution of T22-GFP-H6 and T22-GFP-H5T. 
A. Representative ex vivo tumor fluorescence images (FLI) at 5, 24, and 48 h after iv 
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administration of 100 µg dose of each protein nanoparticle in mice bearing subcutaneous SP5 
CXCR4+ colorectal tumors. B. Quantitation of GFP-emitted fluorescence in tumors, liver and 
kidney at 5, 24, and 48 h using the IVIS spectrum system. C. Representative ex vivo images of 
nanoparticle accumulation in normal mouse organs (brain, lung, liver, kidney, and bone 
marrow) at 5 and 48 h. 
 
 
Figure 4. Comparison of tumor and non-tumor exposure between T22-GFP-H6 and T22-
GFP-H5T in tumor bearing mice. Representation of the area under the curve (AUC) of emitted 
fluorescence intensity (FLI) along time (5-48 h), as a measure of exposure, registered in tumors, 
liver and kidney after 100 g single dose injection of T22-GFP-H6 (A) or T22-GFP-H5T (B) 
proteins in CXCR4+ subcutaneous SP5 patient-derived mouse models. C. Percentage of protein 
accumulation (as measured by the AUC = FLI x hour) in tumor, liver or kidney and total emission 
for both studied proteins. FLI signal from experimental mice was calculated subtracting the FLI 




























Table 1. Main properties of T22-GFP His-rich protein nanoparticles carrying modified 























































































M.M.: Molecular Mass | S.F.: Specific Fluorescence | H.D.: Hydrodynamic Diameter | PDI: Polydispersion Index 
| Zp: Zeta Potential | I.E.: Imidazole Elution 
 
a 
The nomenclatures 6, 3 and 5 refer to the total number of Hhis residues in the C-terminal tag and A, T and E refer 
to alanine, threonine and glutamic amino acids respectively. 
b 
The sequence of T22 is MRRWCYRKCYKGYCYRKCR. 
c 
Underlined segments correspond to the amino acids introduced in the study.  
d 
The linker sequence is GGSSRSS. 
e 
The concentration (mM) of imidazole needed to induce protein elution from Immobilized Metal Ion Affinity 
Chromatography. 
f
 The above values (e) relative to that obtained when eluting T22-GFP-H6. 
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Table 2.  Biodistribution kinetics of T22-GFP-H6 and T22-GFP-H5T proteins in tumor 
and non-tumor organs*  
                      
Organs          Groups             
      
T22-GFP-
H6          
T22-GFP-
H5T     
  5 h   24 h   48 h  5 h   24 h   48 h 
Tumor  57.2 ± 28.7  144.3  116.5 ± 9.2  
124.1 ± 
26.2  20.1 ± 0.4  23.7 ± 23.7 
Brain  26.5 ± 1.7  16.1  28.0 ± 1.7  21.8 ± 7.7  26.8 ± 5.6  23.9 ± 4.3 
Lung & 
heart  5.6 ± 2.1  ND  10.9 ± 1.7  6.0 ± 0.9  5.0 ± 0.6  11.4 ± 1.5 
Liver  21.2 ± 0.3  29.6  19.9 ± 2.0  22.1 ± 22.1  25.0 ± 4.1  28.6 ± 7.6 
Kidney  31.6 ± 1.6  28.6  28.3 ± 6.3  22.1 ± 12.0  23.9 ± 0.7  40.4 ±  10.5 
Bone 
marrow  10.9 ± 8.1  21.8  13.4 ± 0.9  2.5 ± 2.5  9.7 ±  6.7  17.4 ± 1.2 
                          
* Measures of ex vivo fluorescence emission by subcutaneous CXCR4+ SP5 patient-derived tumors  and normal 
mouse organs, as measured by FLI (Protein-buffer Radiant Efficiency / 10
5
) at the indicated time after iv 
injection of the material, using the IVIS Spectrum equipment.
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